The Windsor Framework is a proposed post-Brexit legal agreement between the European Union and the United Kingdom which was announced on 27 February 2023. It is designed to address the problem of the movement of goods between the European Single Market and the United Kingdom in the current Northern Ireland Protocol. 

Please see below information from the UK Government on the Windsor Framework Regulations:

• Windsor Framework (Disclosure of Revenue and Customs Information) Regulations 2023
• The Windsor Framework – goods movements (general) Includes documents on the Green Lane, Duty Reimbursement Scheme, Customs Duty Waiver Scheme and Parcels;
• Updated DBT guidance on the scope and application of Article 10 of the Windsor Framework (State Aid);
• HMRC Guidance on applying for authorisation for the UK Internal Market Scheme if you bring goods into Northern Ireland;
• HMRC Guidance on declaring goods you bring into Northern Ireland “not at risk” of moving to the EU;
• HMRC Guidance on declaring goods using the UK Trader Scheme if you bring goods into NI;
• HMRC Guidance on applying the correct duty to goods you bring into NI from countries outside of the EU and UK;
• Defra Guidance on the “Retail Movement Scheme” for moving pre-packed retail goods (e.g. food, drink, cut flowers and pet food) from GB to NI;
• Defra Guidance on labelling requirements under the Retail Movement Scheme (to be introduced in phases – goods moving to NI only from October 2023, all meat and dairy products in GB and NI from October 2024, all composite products from July 2025);
• HMRC updates to guidance on the Trader Support Service;
• Centrally Authorised Products (CAPs) Bridging Mechanism for medicines until Windsor Framework takes effect on 1 January 2025;

And an additional statutory instrument:

• The Customs (Northern Ireland: Repayment and Remission) (EU Exit) (Amendment) Regulations 2023;

Windsor Framework medicines announcement outlining that from 1 January 2025, new medicines for the UK market will be authorised by UK authorities and will only be able to be sold in the UK. Medicines entering NI will not display features required under the EU FMD.